Trimethoprim-Sulfamethoxazole Treatment for Severe Pertussis in Infants Younger Than 2 months During a Macrolide-Resistant Bordetella pertussis Outbreak: A Case Series
Clicks: 1
ID: 318757
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #37 of 40 articles by views in journal of the pediatric infectious diseases society
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Summary Since 2023, macrolide-resistant Bordetella pertussis (MRBP) has surged worldwide. Six infants aged <2 months completed a 14-day course of trimethoprim-sulfamethoxazole for suspected MRBP infection without significant adverse events. Trimethoprim-sulfamethoxazole may be a tolerable option in infants in MRBP-dominant settings.
| Reference Key |
openalex_W7165961479
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Tatsuki Ikuse, Toshihiro Matsui, Masaki Yamada, Kensuke Shoji, Ito Kato, H Kato, Shotaro Matsumoto, Rinshu Shimabukuro, Nao Otsuka, Chikara Ogimi |
| Journal | journal of the pediatric infectious diseases society |
| Year | 2026 |
| DOI |
10.1093/jpids/piag046
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.